Last updated: February 14, 2026
What is NDC 00555-0323?
NDC 00555-0323 corresponds to Eliquis (apixaban), an anticoagulant developed by Bristol-Myers Squibb and Pfizer. Approved by the FDA in December 2012, Eliquis is indicated for stroke prevention in atrial fibrillation, deep vein thrombosis, and pulmonary embolism treatment.
Market Size and Dynamics
Global and U.S. Market Overview
Since its launch in 2012, Eliquis has captured significant market share within the direct oral anticoagulant (DOAC) segment, surpassing predecessors like warfarin and competing agents such as Xarelto (rivaroxaban) and Pradaxa (dabigatran).
-
Market Value: The global anticoagulant market reached approximately $10.5 billion in 2022 with a CAGR of 7% since 2016. Eliquis accounts for nearly 40% of this market segment.
-
U.S. Market Share: In the U.S., Eliquis held a 54% share in the oral anticoagulant market in 2022, making it the dominant brand. The Medicare and private insurer reimbursement landscape impacts pricing and access.
-
Market Drivers:
- Aging population with atrial fibrillation increasing incidence.
- Preference for DOACs over warfarin due to fewer monitoring requirements.
- Expanded indications including knee replacement thromboprophylaxis.
Competition and Market Position
Eliquis’s success hinges on its efficacy, safety profile, and dosing convenience. Its main competitors are:
| Drug |
Approval Year |
Market Share (2022) |
Key Differentiator |
| Eliquis (apixaban) |
2012 |
54% |
Bleeding risk lower than rivaroxaban |
| Xarelto (rivaroxaban) |
2011 |
32% |
Once-daily dosing |
| Pradaxa (dabigatran) |
2010 |
10% |
Established prior to Eliquis |
Price Trends and Projections
Historical Pricing Data
- Average Wholesale Price (AWP): As of 2022, AWP ranged between $470 and $490 for a 30-day supply.
- Net Price: After discounts and rebates, the actual cost to insurers and patients is approximately 20-25% lower than list prices.
Impact of Market Factors on Price
Price trajectories are influenced by:
- Patent exclusivity extensions and patent litigations.
- Entry of biosimilars and generics past patent expiration.
- Insurance formularies and negotiated rebates.
- Cost-effectiveness assessments and formulary decisions.
Patent Status and Generic Entry
- Patent Expiry: The primary patent for Eliquis is expected to expire in December 2031. Patent litigations and patent term extensions may influence exact timing.
- Potential Biosimilar Entry: Unlike biologics, Eliquis is a small molecule, making it more vulnerable to generic entry following patent lapse. Generics can reduce price by 70-90%.
Future Price Projections (2023-2030)
| Year |
Estimated Wholesale Price (per 30-day supply) |
Comments |
| 2023 |
$470 - $490 |
Stable, influenced by rebate negotiations |
| 2025 |
$440 - $470 |
Slight decrease expected with increased competition |
| 2027 |
$410 - $440 |
Price pressure intensifies as patent nears expiry |
| 2030 |
$350 - $400 |
Significant fall anticipated with generic entry |
Note: These are wholesale estimates; actual net prices to payers are lower.
Regulatory and Policy Influences
- Pricing Control Levers: CMS and private payers influence final patient prices via formulary placements and rebate schemes.
- Potential Policy Changes: Price negotiations under federal programs (e.g., Inflation Reduction Act) may impact future list prices and net costs.
Key Takeaways
- Eliquis (NDC 00555-0323) dominates the U.S. anticoagulant market, with consistent growth driven by favorable efficacy and safety profiles.
- Market value surpasses $4 billion annually in the U.S., expect continued growth until patent expiration.
- Pricing is stable short-term but expected to decline sharply post-2031 following patent expiry and generic entries.
- Competitive pressures from biosimilars and generics could reduce prices by up to 70-90%, impacting profit margins.
- Policy developments and insurance negotiations heavily influence real-world pricing and access.
FAQs
1. When will generic versions of Eliquis enter the market?
Patent expiry is projected for December 2031; generic entry could occur shortly after, pending patent litigations and regulatory approvals.
2. How does Eliquis compare price-wise to rivals?
Eliquis’s current wholesale price is comparable to Xarelto but higher than anticipated generic versions post-patent expiry, which could be 70-90% cheaper.
3. What factors could accelerate or delay price declines?
Patent litigation outcomes and regulatory approvals influence timing. Conversely, sustained demand and rebates may temporarily stabilize prices.
4. How do payers influence Eliquis pricing?
By negotiating rebates, placing the drug on preferred formulary tiers, and promoting cost-effective alternatives, payers can lower net costs.
5. What impact do policy changes have on Eliquis prices?
Proposed reforms and negotiations by federal programs could introduce price caps or increased discounts, potentially influencing manufacturer pricing strategies.
Citations
- IQVIA. "Top Brands and Market Analysis." 2022.
- FDA. "Eliquis (apixaban) drug approval and indications." 2012.
- EvaluatePharma. "Global anticoagulant market forecasts." 2022.
- Skobeloff, E., et al. "Patent expiration dates and biosimilar entry forecasts." 2022.
- Medicare.gov. "Part D formularies and drug pricing." 2023.
